The Gastrointestinal Stromal Tumor (GIST) drugs in development market research report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gastrointestinal Stromal Tumor (GIST). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued products.
GlobalData tracks 65 drugs in development for Gastrointestinal Stromal Tumor (GIST) by 55 companies/universities/institutes. The top development phase for Gastrointestinal Stromal Tumor (GIST) is phase ii with 21 drugs in that stage. The Gastrointestinal Stromal Tumor (GIST) pipeline has 62 drugs in development by companies and three by universities/ institutes. Some of the companies in the Gastrointestinal Stromal Tumor (GIST) pipeline products market are: Deciphera Pharmaceuticals, Bayer and Novartis.
The key targets in the Gastrointestinal Stromal Tumor (GIST) pipeline products market include Mast/Stem Cell Growth Factor Receptor Kit, Platelet Derived Growth Factor Receptor Alpha, and Platelet Derived Growth Factor Receptor Beta.
The key mechanisms of action in the Gastrointestinal Stromal Tumor (GIST) pipeline product include Mast/Stem Cell Growth Factor Receptor Kit Inhibitor with 14 drugs in Filing rejected/Withdrawn. The Gastrointestinal Stromal Tumor (GIST) pipeline products include eight routes of administration with the top ROA being Oral and nine key molecule types in the Gastrointestinal Stromal Tumor (GIST) pipeline products market including Small Molecule, and Monoclonal Antibody.
Gastrointestinal Stromal Tumor (GIST) overview
Gastrointestinal stromal tumors (GISTs) are tumors that occur in the gastrointestinal tract. GISTs belong to a group of cancers called soft tissue sarcomas. GISTs can be benign or malignant. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can be felt with the hand, nausea and vomiting, vomiting blood or having blood in the stool, and fatigue due to anemia (low red blood cell counts). GIST treatment involves surgery, radiation therapy, targeted therapy, and chemotherapy.
For a complete picture of Gastrointestinal Stromal Tumor (GIST)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
